CNCE Concert Pharmaceuticals Inc.

8.15
-0.26  -3%
Previous Close 8.41
Open 8.61
Price To Book 2.38
Market Cap 241,541,501
Shares 29,636,994
Volume 136,343
Short Ratio
Av. Daily Volume 200,577
Stock charts supplied by TradingView

NewsSee all news

  1. Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the details of its pivotal Phase 3 trials of CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or

  2. Concert Pharmaceuticals Reports 2019 Financial Results and Provides Update on Clinical Programs

    CTP-543 Phase 3 Program for Treatment of Alopecia Areata Expected to Begin in 2020 New CTP-543 Patent Covers Pharmaceutical Compositions of CTP-543 and Methods of Treating Alopecia Areata with CTP-543 CTP-692 Phase

  3. Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at the 2020 American Academy of Dermatology Annual Meeting

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that results from its CTP-543 Phase 2 dose-ranging trial in alopecia areata have been selected for an oral presentation at the Late-Breaking Research Program

  4. Concert Pharmaceuticals to Report Full Year 2019 Results on February 27, 2020

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the year ended December 31, 2019, on Thursday, February 27, 2020, before the U.S. financial markets open. The

  5. Concert Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the closing of its previously announced underwritten public offering of 5,735,283 shares of its common stock to the public at $9.92 per share, which included

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated 4Q 2020.
CTP-543
Alopecia areata
Phase 3 trial did not meet primary endpoint - September 27, 2019.
AVP-786
Agitation in patients with Alzheimer's disease
Phase 3 planned. Needs partner
CTP-499
Diabetic Kidney Disease
Phase 2 monotherapy trial initiated 2Q 2019.
VX-561
Cystic fibrosis who have a gating mutation
Phase 2 trial initiation announced December 2, 2019. Data due end of 2020.
CTP-692
Schizophrenia
Phase 2 combo trial initiated May 2019.
VX-561 and VX-121
Cystic Fibrosis

Latest News

  1. Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the details of its pivotal Phase 3 trials of CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or

  2. Concert Pharmaceuticals Reports 2019 Financial Results and Provides Update on Clinical Programs

    CTP-543 Phase 3 Program for Treatment of Alopecia Areata Expected to Begin in 2020 New CTP-543 Patent Covers Pharmaceutical Compositions of CTP-543 and Methods of Treating Alopecia Areata with CTP-543 CTP-692 Phase

  3. Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at the 2020 American Academy of Dermatology Annual Meeting

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that results from its CTP-543 Phase 2 dose-ranging trial in alopecia areata have been selected for an oral presentation at the Late-Breaking Research Program

  4. Concert Pharmaceuticals to Report Full Year 2019 Results on February 27, 2020

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the year ended December 31, 2019, on Thursday, February 27, 2020, before the U.S. financial markets open. The

  5. Concert Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the closing of its previously announced underwritten public offering of 5,735,283 shares of its common stock to the public at $9.92 per share, which included

  6. Concert Pharmaceuticals Announces Pricing of Public Offering

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the pricing of an underwritten public offering of 4,752,420 shares of its common stock at a public offering price of $9.92 per share. In addition, and in lieu

  7. Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by

  8. Concert Pharmaceuticals Announces Federal Circuit Granted its Motion to Vacate and Remand PTAB Decision Involving CTP-543

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) granted the Company's motion to vacate and remand the Patent Trial and Appeal Board (PTAB)

  9. Concert Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata

    Claims cover pharmaceutical compositions of CTP-543 and methods of treating alopecia areata with CTP-543 New patent expected to expire in 2037 Concert expects to advance CTP-543 into Phase 3 evaluation for alopecia

  10. Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it has completed its open label trial evaluating 8 mg twice-daily compared to 16 mg once-daily dosing of CTP-543 in patients with moderate-to-severe

  11. Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia

    CTP-692 Offers Potentially New Approach as an Adjunctive Treatment to Improve Overall Symptoms in Patients with Schizophrenia Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the initiation of a Phase 2

  12. Concert Pharmaceuticals to Present at Upcoming Investor Conferences

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate at the following upcoming investor conferences: The Stifel 2019 Healthcare Conference on November 19, 2019 at 1:50 p.m. ET;

  13. Concert Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Company Update

    Conference Call Scheduled Today at 8:30 a.m. ET Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the third quarter of 2019. "Over the past several months, we have presented important

  14. Concert Pharmaceuticals to Host KOL Webcast Event Focused on CTP-692 and Schizophrenia

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will host a conference call and webcast event with a key opinion leader in the field of psychiatry and schizophrenia on Thursday, November 14, 2019.

  15. Concert Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 7, 2019

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its third quarter 2019 financial results on Thursday, November 7, 2019, before the U.S. financial markets open. The Company will host a

  16. Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV Congress

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today presented results from its recently completed Phase 2 dose-ranging trial of the investigational medicine CTP-543 in patients with moderate-to-severe alopecia areata, an

  17. Concert Pharmaceuticals to Provide Overview of Clinical Pipeline at Cantor Healthcare Conference

    Company developing two proprietary drug candidates based on well‑established biology in alopecia areata and schizophrenia Webcast details for Cantor Healthcare Conference presentation Thursday, October 3, 2019 at 5:20

  18. Concert Pharmaceuticals Names Jeffrey Munsie as Chief Legal Officer

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it has named Jeffrey A. Munsie to the position of Chief Legal Officer. In this role, Mr. Munsie will have overall responsibility for key general corporate

  19. Concert Pharmaceuticals Completes Enrollment in Second Open Label Trial of CTP-543 to Evaluate Once-Daily vs. Twice-Daily Dosing in Patients with Alopecia Areata

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of CTP-543 in

  20. Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will present results from its recently completed Phase 2 trial of CTP-543 in patients with moderate-to-severe alopecia areata. These data will be

  21. Concert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

    CTP-543 Achieved its Primary Endpoint in the 8 mg and 12 mg Twice-Daily Dosing Cohorts Advancement into Phase 3 Evaluation Planned in 2020 Company to Host Investor Conference Call Today at 8:30 a.m. ET Concert

  22. Concert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

    CTP-543 Achieved its Primary Endpoint in the 8 mg and 12 mg Twice-Daily Dosing Cohorts Advancement into Phase 3 Evaluation Planned in 2020 Company to Host Investor Conference Call Today at 8:30 a.m. ET Concert

  23. Concert Pharmaceuticals to Present at Upcoming Investor Conferences

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate at the following upcoming investor conferences: The H.C. Wainwright 21st Annual Healthcare Conference on September 9, 2019 at 8:45